| Income Statement | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|---|
| Total revenues | 304,393 | 983,374 | 1,196,617 | 797,519 |
| Cost of product revenues | 299,263 | 612,527 | 512,510 | 552,287 |
| Gross profit | 5,130 | 370,847 | 684,107 | 245,232 |
| Selling, general and administrative | 2,930,627 | 2,983,284 | 2,633,098 | 2,678,894 |
| Research and development | 768,563 | 849,358 | 1,015,010 | 913,031 |
| Total operating expenses | 3,699,190 | 3,832,642 | 3,648,108 | 3,591,925 |
| Loss from operations | -3,694,060 | -3,461,795 | -2,964,001 | -3,346,693 |
| Other expense, net | -531 | -3,095 | -20,152 | -101 |
| Interest income | 40,267 | 60,340 | 71,440 | 36,295 |
| Unrealized gain on change in fair value of warrants classified as a liability | -6,410 | -68,430 | -244,000 | -5,160,000 |
| (loss) income before provision for income taxes | -3,647,914 | -3,336,120 | -2,668,713 | 1,849,501 |
| Net loss from continuing operations | -3,647,914 | - | - | - |
| Net loss from discontinued operations, net of tax | -336,195 | - | - | - |
| Net (loss) income | -3,984,109 | -3,336,120 | -2,668,713 | 1,849,501 |
| Less net loss attributable to noncontrolling interest | -38,746 | -31,945 | -29,301 | -30,295 |
| Net (loss) income attributable to applied dna sciences, inc | -3,945,363 | -3,304,175 | -2,639,412 | 1,879,796 |
| Deemed dividend related to warrant modifications | 15,500,244 | 23,919,429 | 14,907,223 | - |
| Net (loss) income attributable to common stockholders | -19,445,607 | -27,223,604 | -17,546,635 | 1,879,796 |
| Earnings per share, basic | -34 | -15.35 | -0.56 | 0.47 |
| Earnings per share, diluted | -34 | -15.35 | -0.56 | 0.47 |
| Weighted average number of shares outstanding, basic | 572,018 | 1,773,086 | 31,518,861 | 4,014,261 |
| Weighted average number of shares outstanding, diluted | 572,018 | 1,773,086 | 31,518,861 | 4,014,261 |
APPLIED DNA SCIENCES INC (APDN)
APPLIED DNA SCIENCES INC (APDN)